hotspot -WSS

hotspot

author：fashion 2025-09-29 01:38:28 - browse：737

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Ending racial health disparities hinges on penalties, political will

leisure time

WSS

An outrageous hospital charge: I paid $710 for an hour of babysitting

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Hospitals struggle to profit from CAR

Interest rates are at a 22

Behind warning on Apellis’s eye drug lies a conflict of interest

Stanford president's case begs question: Who takes blame?

focus

hotspot

explore

Duchenne breakthrough therapy leaves behind pioneering families

Driven by the pandemic, applicants flood public health schools

The cancer drug shortage isn’t new — and neither are the solutions

7 more heat

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Sports medicine is finally prioritizing gender equality

Winning ticket for $1 billion Powerball jackpot sold in California

Alkermes shareholders re

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

hotspot

Judge rejects Trump's request to move Stormy Daniels hush

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Alexander Hamilton and the argument for universal insurance

Timeline: Special counsel's probe into Trump's handling of classified documents

Vir antibody drug aimed at influenza A fails in clinical trial

Study identifies new proteins linked to dementia risk 25 years later

leisure time

leisure time

leisure time

Wikipedia